VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Resumes Arena Pharma (ARNA) at Outperform
February 6, 2013 7:14 AM ESTLeerink Swann initiates coverage on Arena Pharma (NASDAQ: ARNA) with a Outperform rating and $11-$12 valuation range.
The firm comments, "Our due diligence points to a significant transformation occurring in the obesity space, similar in scope to smoking cessation a decade... More
VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
February 1, 2013 8:16 AM ESTVIVUS, Inc. (Nasdaq: VVUS) shares are ticking higher in early trading Friday morning following publication of positive results from a "study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and... More
VIVUS (VVUS) Reports Publication of Signifianct Data from Recent Qsymia Study
February 1, 2013 7:15 AM ESTVIVUS, Inc. (Nasdaq: VVUS) announces the publication of a study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these... More
VIVUS (VVUS) Qsymia Prescriptions Jump 140%+ After Free Trial Program Starts
January 7, 2013 6:45 AM ESTVIVUS, Inc. (Nasdaq: VVUS) shares are looking to open higher Monday amid new Qsymia prescription data.
According to Bloomberg, Qsymia prescriptions jumped about 140 percent higher from 5,394 for the four-weeks ended October 26th to 12,978 in the four-week period ended December 21st. The pop came following commencement of its Free Trial program on November 19th through two certified pharmacies.
VIVUS said that a third pharma started the program in late December.
The October data was revised higher from an initial estimate of 4,904 prescriptions.
More color from an 8-K filing made... More
